Sven Borchmann
Impact in
-
- Lymphoma Diagnosis and Treatment
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Viral-associated cancers and disorders
Papers in
-
- Lymphoma Diagnosis and Treatment 43
- Genetic factors in colorectal cancer 6
- Oncology 30
- CAR-T cell therapy research 10
- Cancer Immunotherapy and Biomarkers 10
- Co-authors
- Andreas Engert (23 shared papers)Peter Borchmann (17 shared papers)Stephanie Sasse (10 shared papers)Bastian von Tresckow (16 shared papers)Michael Fuchs (9 shared papers)Paul Jan Bröckelmann (15 shared papers)Horst Müller (7 shared papers)Helen Goergen (6 shared papers)
- Journals
- Blood (8 papers)HemaSphere (8 papers)British Journal of Haematology (5 papers)Annals of Oncology (4 papers)Journal of Clinical Oncology (4 papers)
- Partner nations
- GermanyUnited StatesNetherlands
In The Last Decade
Sven Borchmann
64 papers receiving 1.3k citations
Sven Borchmann's Hit Papers
Peers
Comparison fields: 5 of 83
- Pathology and Forensic Medicine 666
- Oncology 553
- Neurology 174
- Immunology 241
- Genetics 114
Countries citing papers authored by Sven Borchmann
This map shows the geographic impact of Sven Borchmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Borchmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Borchmann more than expected).
Fields of papers citing papers by Sven Borchmann
This network shows the impact of papers produced by Sven Borchmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Borchmann. The network helps show where Sven Borchmann may publish in the future.
Co-authors
The 25 scholars most cited alongside Sven Borchmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 67 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 157 | |
| 2 | 2017 | 101 | |
| 3 | 2016 | 84 | |
| 4 | Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial Hit paper breakdown → | 2024 | 65 |
| 5 | 2020 | 61 | |
| 6 | 2021 | 60 | |
| 7 | 2020 | 55 | |
| 8 | 2013 | 53 | |
| 9 | 2021 | 53 | |
| 10 | 2019 | 45 | |
| 11 | 2021 | 41 | |
| 12 | 2018 | 33 | |
| 13 | 2023 | 29 | |
| 14 | 2019 | 28 | |
| 15 | 2020 | 25 | |
| 16 | 2019 | 25 | |
| 17 | 2017 | 25 | |
| 18 | 2024 | 24 | |
| 19 | 2021 | 21 | |
| 20 | 2017 | 21 |
About Sven Borchmann
Sven Borchmann is a scholar working on Pathology and Forensic Medicine, Oncology, Immunology, Cancer Research and Genetics, having authored 67 papers that have together received 1.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (43 papers), Cancer Genomics and Diagnostics (10 papers), CAR-T cell therapy research (10 papers), Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (9 papers), Immune Cell Function and Interaction (8 papers), Genetic factors in colorectal cancer (6 papers) and Chronic Lymphocytic Leukemia Research (6 papers). The work is most often cited by research in Pathology and Forensic Medicine (666 citations), Oncology (553 citations), Neurology (174 citations), Immunology (241 citations) and Genetics (114 citations). Sven Borchmann has collaborated with scholars based in Germany, United States and Netherlands. Frequent co-authors include Andreas Engert, Peter Borchmann, Stephanie Sasse, Bastian von Tresckow, Michael Fuchs, Paul Jan Bröckelmann, Horst Müller, Helen Goergen, Dennis Alexander Eichenauer and David Matthew Kurtz. Their work appears in journals such as Blood, HemaSphere, British Journal of Haematology, Annals of Oncology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.